Copilot
Your everyday AI companion
Explore these results from Bing
  1. See more
    See more
    See all on Wikipedia
    See more
    Wikipedia
    https://en.wikipedia.org/wiki/Navitoclax

    Navitoclax - Wikipedia

    Navitoclax (previously ABT-263) is an experimental orally active anti-cancer drug, which is a Bcl-2 inhibitor similar in action to obatoclax. Navitoclax inhibits not only Bcl-2, but also Bcl-XL and Bcl-w proteins. Because navitoclax inhibits Bcl-XL, it reduces platelet lifespan, causing thrombocytopenia, and this makes it … See more

    Effects against senescent cells

    In animal studies, navitoclax was found to be a senolytic agent, inducing apoptosis in senescent, but not non-senescent cells. Oral administration of ABT263 to either sublethally irradiated … See more

    Clinical trials

    ABT-263 was studied in 2009. In January 2017, Navitoclax was evaluated as a combination treatment against solid tumors together with See more

    Overview image
    Antisclerotic

    Not directly related to cancer, rather as a therapy for scleroderma, Navitoclax appeared to reduce existing fibrosis through inducing … See more

    Wikipedia text under CC-BY-SA license
    Feedback
  2. PubMed
    https://pubmed.ncbi.nlm.nih.gov/18451170

    ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

    Explore further

    An inhibitor of Bcl-2 family proteins induces regression of …
    nature.com
    Inhibition of Bcl-2/xl With ABT-263 Selectively Kills ... - PubMed
    pubmed.ncbi.nlm.nih.gov
    Recommended to you based on what's popular • Feedback
  3. Nature
    https://www.nature.com/articles/s41419-021-03971-7

    Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven ... - Nature

    Explore further

    Treatment with the BCL-2/BCL-xL inhibitor senolytic drug …
    link.springer.com
    Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven ... - …
    pubmed.ncbi.nlm.nih.gov
    Recommended to you based on what's popular • Feedback
  4. Studies of abt-263
    PubMed
    ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor
    Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL, and Mcl-1) is commonly associated with tumor maintenance, progression, and chemoresistance. We previously reported the discovery of ABT-737, a potent, small-molecule Bcl-2 family protein
    Author: Christin Tse
    Published: 2008/05/01
    Keywords: National In…
    National Center for Biotechnology Information
    Treatment with the BCL-2/BCL-xL inhibitor senolytic drug ABT263/Navitoclax improves functional hyperemia in aged mice
    The prevalence of age-related cognitive impairment is becoming a critical public health concern as proportions of older individuals in populations of many developed countries rapidly grow. Over 20% of people in Japan and many countries in the European
    Author: Stefano Tarant…
    Published: 2021/10
    Publication: GeroScie…
    National Center for Biotechnology Information
    Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis
    Patients with progressive fibrosing interstitial lung diseases (PF-ILDs) carry a poor prognosis and have limited therapeutic options. A hallmark feature is fibroblast resistance to apoptosis, leading to their persistence, accumulation, and excessive deposition
    Author: Joseph C. Coo…
    Published: 2023/02/02
    Publication: JCI Insigh…
    National Center for Biotechnology Information
    ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts
    Background: Inhibiting proliferation and inducing apoptosis of myofibroblasts is becoming one of the promising and effective ways to treat hypertrophic scar. ABT-263, as an orally bioavailable BCL-2 family inhibitor, has showed great antitumor characteristics
    Author: Xiaolan Yang, …
    Published: 2020
    Publication: Front Pha…
    PubMed
    Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction
    Background: The discovery of ABT-263, a rationally designed Bcl-2/Bcl-xL inhibitor at present in Phase I clinical trials for cancer, is described. Emphasis is placed on the specific hurdles overcome throughout the discovery process that relate to the
    Author: Michael D Wendt
    Published: 2008/9
    Keywords: The discov…
    National Center for Biotechnology Information
    The Bcl-2/Bcl-xL Inhibitor ABT-263 Attenuates Retinal Degeneration by Selectively Inducing Apoptosis in Senescent Retinal Pigment Epithelial Cells
    Age-related macular degeneration (AMD) is one of the leading causes of blindness in elderly individuals. However, the currently used intravitreal injections of anti-vascular endothelial growth factor are invasive, and repetitive injections are also accompanied
    Author: Wonseon Ryu…
    Published: 2023/07/07
    Publication: Mol Cells…
  5. ASCO Publications
    https://ascopubs.org/doi/10.1200/JCO.21.0…

    Addition of Navitoclax to Ongoing Ruxolitinib Therapy …

    WebFeb 18, 2022 · Navitoclax (ABT-263) is an orally bioavailable, small-molecule BCL-2 homology 3 mimetic that binds with high affinity (K i ≤ 1 nmol/L) to prosurvival BCL-2 family proteins (BCL-X L, BCL-2, and BCL …

    Tags:
    ABT-263
    Bcl-2
  6. Nature
    https://www.nature.com/articles/s41467-022-35657-9

    Targeting anti-apoptotic pathways eliminates senescent ... - Nature

  7. Explore abt-263

  8. Nature
    https://www.nature.com/articles/aps201778

    ABT-263 induces G1/G0-phase arrest, apoptosis and autophagy in …

    Tags:
    ABT-263
    Bcl-2
    Cancer Treatment
    Navitoclax Clinical Trials
  9. Frontiers
    https://www.frontiersin.org/journals/pharmacology...

    Frontiers | Clinical Review: Navitoclax as a Pro-Apoptotic and Anti ...

    Tags:
    ABT-263
    Bcl-2
  10. National Center for Biotechnology Information
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599595

    Treatment with the BCL-2/BCL-xL inhibitor senolytic drug ABT263 ...

    Tags:
    Publish Year:2021
    GeroScience. 2021 Oct; 43(5): 2427-2440.
    Published:2021/10
  11. American Association for Cancer Research
    https://aacrjournals.org/cancerres/article/68/9/...

    ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

    Tags:
    Bcl-2
    Abt-263 Mechanism of Action
    Cancer Treatment
    Abt 263 Senolytic
  12. Taylor & Francis Online
    https://www.tandfonline.com/doi/full/10.108…

    Safety and efficacy of navitoclax, a BCL-2 and BCL-X

    WebNov 25, 2020 · The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol . 2010;66(5):869–880. PubMed Web of Science …

    Tags:
    ABT-263
    Bcl-2
    Publish Year:2021
    Navitoclax Clinical Trials
  15. Some results have been removed